GlassScriptPhysician profile
Cheryl K Johnson
NPI 1164419693
$9,390.14
in general payments reported to CMS, 2019-2025
39 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $1,295 · 2021: $1,987 · 2022: $1,343 · 2023: $1,214 · 2024: $1,279 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,535 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,534.63 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,854.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,066.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $760.91 | 2021-2025 | |
| Lilly USA, LLC | $638.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $516.06 | 2019-2023 | |
| Astellas Pharma US INC | $508.68 | 2019-2023 | |
| Abbott Laboratories | $378.99 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $376.55 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.69 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $350.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $343.11 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $262.15 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $240.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $232.20 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $189.34 | 2021-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.